U.S. Merck Looks For Developing Country Markets
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck's second-quarter results demonstrate the risks and rewards of becoming less U.S.-centric. Emerging markets expansion and new product launches outside of the U.S. drove growth, but EU price cuts dampened revenues and profits.